Quick Answer
WEST PHARMACEUTICAL SERVICES INC reported R&D Expense of $74.30 million for fiscal year 2025.
WEST PHARMACEUTICAL SERVICES INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $74.30M | +7.5% |
| 2024 | $69.10M | +1.0% |
| 2023 | $68.40M | +16.9% |
| 2022 | $58.50M | +10.8% |
| 2021 | $52.80M | +12.6% |
| 2020 | $46.90M | +20.6% |
| 2019 | $38.90M | -3.5% |
| 2018 | $40.30M | +3.1% |
| 2017 | $39.10M | +6.2% |
| 2016 | $36.80M | +7.9% |
| 2015 | $34.10M | -8.6% |
| 2014 | $37.30M | -1.6% |
| 2013 | $37.90M | +14.2% |
| 2012 | $33.20M | +14.1% |
| 2011 | $29.10M | +21.8% |
| 2010 | $23.90M | +20.1% |
| 2009 | $19.90M | +6.4% |
| 2008 | $18.70M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $17.10M | +10.3% | -10.5% |
| June 30, 2025 | $19.10M | +9.1% | +17.2% |
| March 31, 2025 | $16.30M | -7.4% | +5.2% |
| September 30, 2024 | $15.50M | -5.5% | -11.4% |
| June 30, 2024 | $17.50M | +6.1% | -0.6% |
| March 31, 2024 | $17.60M | +2.9% | +7.3% |
| September 30, 2023 | $16.40M | +20.6% | -0.6% |
| June 30, 2023 | $16.50M | +14.6% | -3.5% |
- WEST PHARMACEUTICAL SERVICES INC showed an increase of +7.5% in R&D Expense compared to the prior fiscal year.
- Over the 2008–2025 period, WEST PHARMACEUTICAL SERVICES INC’s r&d expense has grown by 297.3% (from $18.70 million to $74.30 million).
- The most recent figure is from WEST PHARMACEUTICAL SERVICES INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: